Global Lupus Market size was valued US$ 1.67 Bn. in 2019 and the total revenue is expected to grow at 12.41% from 2019 to 2027, reaching nearly US$ XX Bn.
Global Lupus Market
The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.
Lupus is a chronic autoimmune disease that causes inflammation all over the body. In patients with lupus, the immune system attacks its own tissues and can damage several parts of the body including kidney, heart, skin, joints, lungs, brain, and blood vessels. Lupus patients may be at higher risk of developing severe infections if they develop COVID-19.
The market for lupus is expanding at breakneck speed across the world because of the surging prevalence of lupus and the ongoing medical developments in treating systemic lupus erythematosus. The increased R&D activities for lupus can be considered a driving factor. Throughout the world, approximately 5 million people suffer from lupus and 70% of the total cases are systemic lupus erythematosus. As per the Lupus Foundation of America, approximately 1.5 million Americans have a form of lupus, and around 16,000 new cases are reported yearly in the Americans. However, stringent regulatory guidelines for new drugs and the cost restraint are expected to be among the primary hindrance. Likewise, the MMR report covers all the trends and technologies playing a major role in the growth of the lupus market over the 2019-2027. It highlights the drivers, restraints, and opportunities expected to influence the lupus market growth during the forecast period.
North America’s lupus market was valued at US$ XX.12 Mn. in 2019 and is expected to reach a value of US$ XX.89 Mn. by 2027, with a CAGR of XX.50% during the forecast period. This is owing to the availability of reimbursement, growing demand for better treatment options, rising prevalence of lupus, government initiatives for lupus. Moreover, the developed healthcare infrastructure and accessibility to biologics are likely to contribute to the lupus market growth in the region.
The U.S. has the highest number of people diagnosed from LN in 2017, followed by the U.K. and Japan. The prevalence of lupus nephritis in the AAPC SLE patient population is much higher than in Caucasians. Therefore, it represents a large and well-defined market opportunity with very little competition and is expected to be worth US$ XX.89 billion by 2019 at a CAGR of XX.29 %.
The report covers the segments in the lupus market such as application, technique, and product. By product, the immunosuppressant segment is expected to continue to hold the largest XX.85% share in the lupus market because of its low cost and high accessibility. However, the biologics segment holds the second-largest share in the lupus market and it is expected to grow at a CAGR of XX.15 % during the forecast period. The introduction of new biologics with improved efficacy is probable to support the growth of the global market.
In recent years, major companies in the lupus market have taken several strategic measures, such as facility expansions and partnerships. In July 2017, GlaxoSmithKline Company received approval from the FDA for developing a novel self-injectable formulation of Benlysta which can treat systemic lupus erythematosus in adults. The use of Benlysta has exposed a decrease and improvements in the ingesting of anti-inflammatory glucocorticoids.
The GlaxoSmithKline Company is further conducting advanced product development, clinical trials, and combination therapy studies with rituximab to upsurge the opportunities for the therapy. The advent of numerous new biological or natural treatments is adding to the treatment options and drug costs, so inflating the growth of the lupus market.
The objective of the report is to present a comprehensive analysis of the Global Lupus Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global Lupus Market dynamics, structure by analyzing the market segments and projects the Global Lupus Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Lupus Market make the report investor’s guide.
visit at-https://www.maximizemarketresearch.com/market-report/global-lupus-market/65753/
Scope of the Global Lupus Market
Global Lupus Market, by Technique
• Systemic Lupus Erythematosus
• Cutaneous Lupus Erythematosus
• Drug-Induced Lupus Erythematosus
• Neonatal Lupus
Global Lupus Market, by Product
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Antimalarial Drugs
• Corticosteroids
• Immunosuppressants
• Biologics
• Others
Global Lupus Market, by End User
• Hospital & Clinics
• Diagnostic Laboratories
• Others
Global Lupus Market, by Region
• Asia Pacific
• North America
• Europe
• South America
• Middle East & Africa
Key players operating in the Global Lupus Market
• Aurinia Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Cadila Healthcare
• GlaxoSmithKline plc
• Mylan N.V.
• F. Hoffmann-La Roche AG
• Pfizer, Inc.
• Sanofi
• Lycera Corporation
• Merck KGaA
About Us:
Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Contact info:
Name: Vikas Godage
Organization: Maximize Market Research Pvt.Ltd.Pune
Email: sales@maximizemarketresearch.com
Contact: +919607065656 / +919607195908
Website:www.maximizemarketresearch.com
